Macrophage Therapeutics to Present at BIO2015 Conference

DUBLIN, Ohio--(BUSINESS WIRE)-- Macrophage Therapeutics, Inc. a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), announces that James Goldschmidt, Ph.D., Macrophage Therapeutics’ Chief Operating Officer, will present at the Biotechnology Industry Organization (BIO) 2015 International Convention on Tuesday, June 16, 2015, at 3:00 p.m. EDT in Theater 1. The conference will be held at The Pennsylvania Convention Center (June 15-18, 2015, Philadelphia, PA).

A live webcast of Dr. Goldschmidt’s presentation can be accessed at the following URL: An archived version of the webcast will be available and can be accessed within the Investors' section of the Navidea website at

About Macrophage Therapeutics, Inc.

Macrophage Therapeutics, Inc., a newly created subsidiary of Navidea Biopharmaceuticals, Inc. (NAVB), is developing therapeutics using the patented Manocept™ immunotherapy platform licensed from Navidea to target over-active macrophages implicated in cancer, cardiovascular, central nervous system, autoimmune, antiviral, and skin diseases. Manocept specifically targets CD206, or mannose receptor prevalent on over-active macrophages. The technology enables highly specific targeted delivery of active (either existing or yet to be developed) agents that can modulate the activity of over-active macrophages that have been implicated in many diseases. Targeted delivery should significantly enhance a given compound’s efficacy and safety. For more information, please visit the Company's web site at

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit

Navidea Biopharmaceuticals
Tom Baker, 617-532-0624
Sharon Correia, 978-655-2686
Associate Director, Corporate Communications

Source: Navidea Biopharmaceuticals, Inc.